Collegium PharmaceuticalCOLL
About: Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Employees: 357
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
176% more call options, than puts
Call options by funds: $47K | Put options by funds: $17K
6% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 81
4% less capital invested
Capital invested by funds: $1.1B [Q1] → $1.05B (-$44.9M) [Q2]
6.02% less ownership
Funds ownership: 116.7% [Q1] → 110.69% (-6.02%) [Q2]
10% less funds holding
Funds holding: 240 [Q1] → 217 (-23) [Q2]
41% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 34
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Brandon Folkes | 14%upside $44 | Buy Assumed | 11 Aug 2025 |
Financial journalist opinion
Based on 6 articles about COLL published over the past 30 days
